Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,096,341

« Back to Dashboard
Patent 6,096,341 protects WELLBUTRIN XL and is included in one NDA. There has been one Paragraph IV challenge on Wellbutrin XL.

Summary for Patent: 6,096,341

Title: Delayed release tablet of bupropion hydrochloride
Abstract:The invention provides a controlled release tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer.
Inventor(s): Seth; Pawan (Irvine, CA)
Assignee: Pharma Pass LLC (Irvine, CA)
Application Number:09/184,091
Patent Claim Types:
see list of patent claims
Dosage form; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 4th percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Valeant Intl
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL021515-001Aug 28, 2003RXNo6,096,341Oct 30, 2018
Valeant Intl
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL021515-002Aug 28, 2003RXYes6,096,341Oct 30, 2018
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,096,341

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,327 Delayed release coated tablet of bupropion hydrochloride<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.